Impact of a (poly)phenol-rich extract from the brown algae Ascophyllum nodosum on DNA damage and antioxidant activity in an overweight or obese population: a randomized controlled trial by Baldrick, Francina R et al.
Impact of a (poly)phenol­rich extract from 
the brown algae Ascophyllum nodosum on  
DNA damage and antioxidant activity in an  
overweight or obese population: a 
randomized controlled trial 
Article 
Accepted Version 
Baldrick, F. R., McFadden, K., Ibars, M., Sung, C., Moffatt, T., 
Megarry, K., Thomas, K., Mitchell, P., Wallace, J. M. W., 
Pourshahidi, L. K., Ternan, N. G., Corona, G., Spencer, J., 
Yaqoob, P., Hotchkiss, S., Campbell, R., Moreno­Rojas, J. M., 
Cuevas, F. J., Pereira­Caro, G., Rowland, I. and Gill, C. I. R. 
(2018) Impact of a (poly)phenol­rich extract from the brown 
algae Ascophyllum nodosum on DNA damage and antioxidant 
activity in an overweight or obese population: a randomized 
controlled trial. American Journal of Clinical Nutrition, 108 (4). 
pp. 688­700. ISSN 0002­9165 doi: 
https://doi.org/10.1093/ajcn/nqy147 Available at 
http://centaur.reading.ac.uk/80133/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work. 
To link to this article DOI: http://dx.doi.org/10.1093/ajcn/nqy147 
Publisher: American Society for Nutrition 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
1 
 
 
Impact of a (poly)phenol-rich extract from the brown algae Ascophyllum nodosum on 1 
DNA damage and antioxidant activity in an overweight/obese population 2 
 3 
Francina R. Baldricka, Kevin McFaddena, Maria Ibarsa, Chris Sunga, Keith Thomasb, Peter 4 
Mitchella, Julie M.W. Wallacea, L. Kirsty Pourshahidia, Nigel G Ternana , Giulia Coronac,d, 5 
Jeremy Spencerc, Parveen Yaqoobc, Sarah Hotchkisse, Ross Campbelle, José Manuel Moreno-6 
Rojasf, Francisco Julián Cuevasf, Gema Pereira-Carof , Ian Rowlandc, Chris I.R. Gill*a 7 
 8 
aNutrition Innovation Centre for Food and Health, Centre for Molecular Biosciences, 9 
University of Ulster, Cromore Road, Coleraine, N. Ireland, BT52 1SA, UK 10 
bSchool of Biomedical Sciences, Centre for Molecular Biosciences, University of Ulster, 11 
Cromore Road, Coleraine, N. Ireland, BT52 1SA, UK 12 
cHugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, 13 
University of Reading, P.O. Box 226, Whiteknights, Reading RC6 6AP, UK 14 
dHealth Sciences Research Centre, University of Roehampton, London, SW15 4JD, UK 15 
eCyberColloids Ltd., Carrigaline Industrial Estate, Carrigaline, County Cork, Ireland 16 
fDepartment of Food Science and Health, IFAPA-Alameda del Obispo, Córdoba, Spain 17 
 18 
*Corresponding author. Tel: 02870123181 19 
E-mail address: c.gill@ulster.ac.uk (C. Gill)  20 
 21 
Supported by funding from the European Union Seventh Framework Programme managed by 22 
REA-Research Executive Agency http://ec.europa.research/rea (FP7/2007-2013) under grant 23 
agreement No. 262519. 24 
 25 
2 
 
 
Running head: Seaweed phenolics, Ascophyllum nodosum, inflammation, DNA damage, C-26 
reactive protein (CRP) 27 
 28 
Abbreviations used: SPE, seaweed (poly)phenol  extract; CRP, C-reactive protein; CVD, 29 
cardiovascular disease; ROS, reactive oxygen species; TNF-α, tumour necrocis factor alpha; 30 
COX, cyclooxygenase; UUREC, University of Ulster Research Ethics Committee; WISP, 31 
Weighed Intake Software Program; TF, tissue factor; TOC, Total oxidative capacity; TMB, 32 
tetramethylbenzidine; IL, interleukin; IFN, interferon; TNF, tumour necrosis factor; UHPLC-33 
HRMS: ultra-high performance liquid chromatography-high resolution-mass spectrometry; 34 
VIP: variable of importance in projection; OPLS-DA: Orthogonal Partial Least Square 35 
Discriminant Analysis. 36 
 37 
This trial was registered at clinicaltrials.gov as NCT02295878. 38 
 39 
Names for PubMed indexing: Baldrick, McFadden, Ibars, Sung, Thomas, Mitchell, Wallace, 40 
Pourshahidi, Ternan, Corona, Spencer, Yaqoob, Hotchkiss, Campbell, Moreno-Rojas, Cuevas, 41 
Pereira-Caro, Rowland, Gill. 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
3 
 
 
ABSTRACT 51 
Background: Epidemiological evidence suggests a diet rich in (poly)phenols has beneficial 52 
effects on many chronic diseases. A rich source of (poly)phenols can be found in brown 53 
seaweed.  54 
Objective: The aim of this study was to investigate the bioavailability and effect of a 55 
seaweed (poly)phenol extract from Ascophyllum nodosum on DNA damage, oxidative stress, 56 
and inflammation in vivo. 57 
Design: A randomised double-blind placebo-controlled crossover trial was conducted in 80 58 
participants aged 30-65 years with a BMI ≥25kg/m2. The participants consumed either a 400 59 
mg capsule containing 100 mg of seaweed (poly)phenol and 300 mg maltodextrin or a 400 mg 60 
maltodextrin placebo control capsule daily for an 8-week period.  Bioactivity was assessed 61 
with a panel of blood-based markers including lymphocyte DNA damage, plasma oxidant 62 
capacity, C-reactive protein and inflammatory cytokines. To explore the bioavailability of 63 
seaweed phenolics, an untargeted metabolomics analysis of urine and plasma samples 64 
following seaweed consumption was determined by UHPLC-HR-MS.  65 
Results: Consumption of the seaweed (poly)phenols resulted in a modest decrease DNA 66 
damage but only in a subset of the total population who were obese. There were no significant 67 
changes in CRP, antioxidant status, inflammatory cytokines or isoprostanes. We identified 68 
phlorotannin metabolites including pyrogallol/phloroglucinol-sulfate, hydroxytrifurahol A-69 
glucuronide, dioxinodehydroeckol-glucuronide, diphlorethol sulfates, C-O-C dimers of 70 
phloroglucinol sulfate, C-O-C dimers of phloroglucinol and diphlorethol sulfate are considered 71 
potential biomarkers of seaweed consumption. 72 
Conclusion: To the best of our knowledge, our work represents the first comprehensive 73 
study in human participants investigating the bioactivity and bioavailability of seaweed 74 
(poly)phenolics. There was a modest improvement in DNA damage but only in the obese subset 75 
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of the total population, and several biomarkers of seaweed consumption, further studies 76 
involving stratification according to weight are required to elucidate these findings. 77 
 78 
Key words: Seaweed, Phenolic compounds, Inflammation, DNA damage, Oxidative stress, 79 
bioavailability 80 
81 
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INTRODUCTION 82 
Diets rich in plant-derived foods protect may against chronic degenerative diseases, 83 
including cardiovascular disease (CVD), effects attributable in part to highly bioactive 84 
(poly)phenolic compounds contained therin (1-3). Fruits and vegetables are a well-known 85 
source of (poly)phenols but a less familiar source rich in (poly)phenolic compounds is brown 86 
algae which uniquely contains phlorotannins (4) for example .Ascophyllum nodosum, a brown 87 
alagae common to the British Isles, that is rich in phlorotannin (5).  Phlorotannins are oligomers 88 
of phloroglucinol whose concentration in seaweed is affected by numerous factors including 89 
plant size and age, water salinity, nutrient and heavy metal content, and light intensity changes 90 
(6-8).  91 
Phlorotannins, and more commonly brown seaweed extracts, beneficially effect a range of 92 
biological processes including modulation of inflammation; reduction of oxidative stress and 93 
improvement in cardiovascular function (9-11). However, the evidence base depends heavily 94 
upon cell and small animal models with few studies involving humans (12-13). Moreover, 95 
species relevance also becomes an issue; in Southeast Asia, Ecklonia and Eisenia are 96 
considered commercially important seaweed species, while from a European perspective 97 
Ascophyllum nodosum is of interest as it is one of only a few commercially sustainable seaweed 98 
species.  99 
Phlorotannin-rich extracts from brown seaweeds have been shown to be effective in 100 
controlling inflammation via a number of pathways including inhibition of pro-inflammatory 101 
cytokines including tumour necrosis factor (TNF)-α and interleukins (IL)-1β and IL-6 (14). 102 
Extracts from Ascophyllum nodosum and other Fucoid species have shown efficacy in 103 
mitigating the effects of oxidative stress by playing an inhibitory role in the generation of 104 
reactive oxygen species (ROS); in preventing DNA damage and also in stimulating the 105 
production of glutathione in affected cells (15-19).  Our  initial in vitro (15) and acute in vivo 106 
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(20) studies on the Ascophyllum nodosum extract(s) demonstarted antioxidant and anti-107 
inflammatory activity, suggesting that the potential antioxidant and anti-inflammatory benefits 108 
from longer term consumption of Ascophyllum nodosum-derived (poly)phenols was worthy of 109 
further investigation in vivo. 110 
A few human and in vitro studies have been conducted in relation to the bioactivity of 111 
phlorotannin rich extracts from Fucoid species. Clinical studies have been used to evaluate the 112 
safe consumption of some of these extracts including a (poly)phenol-enriched extract of the 113 
brown seaweeds Ascophyllum nodosum and Fucus vesiculosus and its effects of on glycaemic 114 
response to sucrose (21). However, to the best of our knowledge, the current investigation is 115 
the first clinical study aimed to specifically address the effect of a phlorotannin-rich extract 116 
from Ascophyllum nodosum on oxidative damage to DNA, plasma antioxidant capacity, 117 
inflammatory responses and chronic, low level inflammation in vivo. 118 
 119 
PARTICIPANTS AND METHODS 120 
Seaweed material  121 
Fresh Ascophyllum nodosum was supplied by The Hebridean Seaweed Company, Isle of 122 
Lewis, Scotland in March 2011. The seaweed biomass was harvested by hand to ensure quality, 123 
cleaned of any contaminating sand and fouling organisms and then shipped refrigerated to the 124 
processing facility (CEVA) in France where it was immediately chopped and frozen. 125 
Preparation of food-grade seaweed extracts and capsule   126 
A novel (poly)phenol-rich seaweed extract from Ascophyllum nodosum was produced by 127 
CEVA (France) using food grade solvent based (ethanol:water, 60:40) extraction system that 128 
was specifically developed for use with fresh or frozen Ascophyllum nodosum. Approximately 129 
half of the produced extract was then fractionated using tangential flow ultra-filtration to 130 
produce further extracts of varying molecular weight range and with varying (poly)phenol 131 
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content. A standardised blended (poly)phenol-rich Ascophyllum nodosum extract was 132 
formulated by CEVA (Table 1) using 175 mg of extract and 50 mg of high molecular weight 133 
fraction (>10 kDa cut off) for use in the current study, so as to maximise the seaweed 134 
(poly)phenol content (>100 mg per day) avaliable form the extraction of  fresh or frozen 135 
Ascophyllum nodosum against the need to minimise the level of iodine to within accepted 136 
regulatory guidelines (<500 μg per day), potential for heavy metal contamination was also 137 
assessed (Table 1). Maltodextrin (175 mg) was added to the capsule formulation as an 138 
excipient. Blending was carried out at the food grade CEVA facilities in France. Samples of 139 
400 mg of the Ascophyllum (poly)phenol rich blend (SPE) or a placebo which contained 400 140 
mg maltodextrin  of and no seaweed (poly)phenols were packed into identical white, opaque, 141 
vegetarian capsules by Irish Seaweeds, Belfast, UK and identically sized and match capsules 142 
used for the clinical study. The food grade seaweed capsule was characterized by NP-HPLC 143 
and LC-MS analysis and has been reported previously (20) (see supplemental figure 2 & 3). 144 
Phlorotannins were quantified using the Folin-Ciocalteau Method (22) using phloroglucinol as 145 
the standard. In brief, 1 mL of suitability diluted sample was reacted with 1.00 mL of 40 % 146 
Folin Ciocalteu reagent for 5 min, and then made alkaline with the addition of 1.00 ml of 100 147 
g/L Na2CO3. Absorbance was read at 730 nm after the solution had developed for 1 h at room 148 
temperature. Phloroglucinol dihydrate (0-30 mg/L) was used as the standard and was treated 149 
in the same way as samples. 150 
 151 
Ethics and participants 152 
Ethical approval was received from the Ulster University Research Ethics Committee 153 
(UUREC). All participants gave written informed consent. Participants were recruited between 154 
May 2011 and August 2011 from Ulster University and the surrounding area. The intervention 155 
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study ran between August 2011 and February 2012. The study was registered at 156 
clinicaltrials.gov as NCT02295878.  157 
The study was conducted in 80 participants (age range 30-65 years). All participants were 158 
apparently healthy, non-smoking, BMI≥25 kg/m2, omnivores, who did not habitually use 159 
vitamin or mineral supplements, as determined using a pre-screening health and lifestyle 160 
questionnaire. Pregnant and lactating women, vegetarians and vegans and lactose intolerant 161 
individuals were excluded from the study, as were those with chronic medical complications 162 
such as diabetes; cardiovascular diseases; autoimmune/inflammatory disorders or those who 163 
had chronic medication use including anti-inflammatory agents.  164 
 165 
Study design 166 
The study was a 24-week randomised, double-blind, placebo-controlled crossover trial. 167 
After obtaining consent, participants were randomly assigned, in blocks of four using a 168 
random-number generator (www.randomization.com), to either the intervention or the control. 169 
In total, eighty participants were randomised to 2 groups of 40, each starting on either a 400 170 
mg seaweed (poly)phenol  extract (SPE) capsule containing 100mg of (poly)phenols or a 400 171 
mg maltodextrin placebo control capsule (Avebe MD14P) daily for an 8-week period. The 172 
participants were supplied with all capsules in weekly labelled capsule boxes at the beginning 173 
of each phase, which was interspersed by an 8-week washout phase. During the washout phase, 174 
the participants were asked to maintain their habitual diet. Participants were asked to bring any 175 
unconsumed capsules to their study appointment at the end of each treatment phase. 176 
Participants were also contacted weekly by the study researcher to encourage compliance and 177 
to discuss any difficulties they were experiencing.  178 
 179 
 180 
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Blood and urine sample collection 181 
Fasting blood samples were collected before and after each phase (week 0, week 8, week 182 
16, and week 24) by venepuncture into EDTA, serum or sodium heparin-containing tubes, as 183 
required. All blood samples were processed on ice. Lymphocytes were isolated by using 184 
Histopaque-1077, according to the manufacturer’s instructions (Sigma Diagnostics, St Louis, 185 
MO), and plasma samples were prepared by centrifugation at 1000 x g for 10 min at 4ºC. Serum 186 
samples were allowed to clot for 30 min at room temperature and then were centrifuged at 2000 187 
x g for 10 min at 4ºC. Whole blood from sodium-heparin treated tubes was prepared according 188 
to the manufacturer’s instructions (BD Bioscience Fast Immune Cytokine System) and 24-hour 189 
urine samples were prepared by centrifugation at 1000 x g for 10 min at 4ºC. Whole blood, 190 
plasma, serum and urine samples were immediately stored at -80ºC, whereas lymphocytes were 191 
stored frozen in liquid nitrogen. All biological measurements were carried out at the end of the 192 
intervention in batches containing equal numbers of active and control phase samples in each 193 
batch, and the researchers were blinded to these samples during analyses. A 24hr urine 194 
collection occurred at each time point, volume and pH was measured. The urine sample was 195 
mixed and 2x 14ml aliquots removed, centrifuged at 3000rpm for 10 minutes, supernatant was 196 
stored -80ºC until use. 197 
 198 
Questionnaire assessments 199 
All participants completed a health and lifestyle questionnaire assessing their alcohol intake 200 
and physical activity levels, as well as a validated 4-day food diary at the mid-point during 201 
each treatment phase (active/placebo) of the study. Data on type of food and corresponding 202 
weight was entered into a food analysis database (WISP, Weighed Intake Software Program; 203 
Tinuviel Software, Warrington, U.K.) by two independent researchers and the dietary 204 
composition calculated.  205 
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 206 
DNA damage in peripheral blood mononuclear cells 207 
Peripheral blood lymphocytes, previously isolated and stored in liquid nitrogen, were 208 
thawed and screened for basal single strand breaks (SBs) in DNA using the single cell gel 209 
electrophoresis (Comet) assay (23) and adapted by Gill et al. (24). Spontaneous DNA SBs are 210 
associated with an altered cell function spontaneous DNA SBs are considered appropriate for 211 
the substantiation of health claims in the context of protection against generic DNA 212 
damage (25). In addition, resistance to induced DNA damage (SB) was measured in 213 
lymphocytes subjected to increased oxidative insult ex vivo by pre-treating lymphocytes with 214 
150µmol H2O2/L for 5 min at 4°C, before the measurement of SBs. The mean (percentage 215 
DNA in tail) was calculated from 50 cells per gel (each sample in triplicate) and the mean of 216 
each set of data were used in the statistical analysis. 217 
 218 
Plasma total oxidative capacity 219 
Total oxidative capacity (TOC) measures total peroxide levels in plasma, by the reaction of 220 
endogenous peroxides with peroxidases, using tetramethylbenzidine (TMB) as the 221 
chromogenic substrate (26). The blue colour of TMB turns to yellow after addition of the stop 222 
solution and can be measured photometrically at 450 nm. For the assay protocol, 10 μl of 223 
standard (freshly-prepared hydrogen peroxide, 0-1 mmol/L) and samples were incubated with 224 
200 μl of the reaction mixture consisting of a reaction buffer (phosphate-citrate buffer 0.05M, 225 
pH 5.0), TMB solution (1 mg/ml), and peroxidase (>2500U/ml) in a proportion of 100:10:1 in 226 
uncoated microtiter plates and incubated at room temperature for 15 min. 50 μl of stop solution 227 
(2MH2SO4) were added into all wells and the absorbance at 450 nm was measured using a 228 
microplate reader (GENIOS Tecan). Hydrogen peroxide standard solutions (0-1 mmol/L) for 229 
calibration curve were freshly prepared before use. 230 
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 231 
Lipid profile and serum C-reactive protein  232 
Plasma total cholesterol, HDL cholesterol and triglycerides were measured on an Instrument 233 
Laboratory (ILAB) 600 (Warrington, UK) autoanalyzer using commercial kits (Roche 234 
diagnostics, Lewis, UK) according to kit manufacturer’s protocols. Plasma LDL cholesterol 235 
was calculated using the Friedewald formula (27). 236 
C-reactive protein, an acute phase protein synthesized by the liver in response to 237 
inflammatory stimuli, especially the cytokine interleukin (IL)-6, was determined on an ILAB 238 
600 autoanalyser using a quantex CRP Ultra-Sensitive commercial kit (0.4-18.3 µg/dl) in 239 
accordance with manufacturer’s instructions. 240 
 241 
Measurement of inflammatory markers 242 
Intracellular cytokine levels in lymphocyte and monocyte populations and tissue factor (TF) 243 
expression were assessed using a whole blood labelling method that utilises flow-cytometry 244 
(Fast Immune Cytokine System, BD Biosciences) in accordance with manufacturer’s 245 
instructions for all participants at all time-points. The method was used to measure intracellular 246 
IL-1, IL-2, IL-6, IL-10, IL-12, interferon (IFN)- and tumour necrosis factor (TNF)- 247 
expression in mononuclear cells. Briefly, whole blood was incubated with either 248 
lipopolysaccharide or phorbol 12-myristate 13-acetate to activate monocytes and lymphocytes, 249 
respectively. Cells were labelled with the appropriate cell surface antibody and cytokine-250 
specific antibody and analysed on a Gallios flow cytometer (Beckman Coulter). The number 251 
and percentage of each cell type expressing the cytokine, as well as the mean channel 252 
fluorescence was recorded. The cytokine profiles were examined by ratio of TNF-α to IL-10, 253 
IL-1β to IL-10, IL-6 to IL-10 and CRP to IL-10, according to Laird et al. (29).  254 
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Isoprostanes have been established as chemically stable, highly specific and reliable 255 
biomarkers of in vivo oxidative stress, and were measured in frozen serum samples using a 256 
commercial 8-Isoprostane EIA Kit (Item no. 516351, Cayman Chemicals). This assay is based 257 
on the competition between 8-isoprostane and an 8-isoprostane acetylcholinesterase (Ache) 258 
conjugate (8-Isoprostane Tracer) for a limited number of 8-isoprostane-specific rabbit 259 
antiserum binding sites consequently 8-isoprostane concentrations are measured as a function 260 
of turbidity (absorbance). 261 
 262 
Processing of urine and plasma.  263 
Urine samples were defrosted, vortexed, centrifuged at 16110 g for 10 min at 5 °C, and 264 
passed through 0.45 μm filter discs prior to the analysis of 50 μL aliquots by UHPLC-HR-MS. 265 
The extraction of metabolites from the plasma samples has been carried out as described 266 
previously (28). Briefly, plasma samples were defrosted, vortexed and 400 µL aliquots were 267 
mixed with 10 µL of ascorbic acid (10%, v/v), and 980 µL of 1% formic acid in acetonitrile. 268 
One µg of rutin was added to the samples as internal standard for plasma extraction efficiency. 269 
The samples were then vortexed for 1 min and ultrasonicated for 10 min. After centrifugation 270 
at 16,110 g for 15 min, supernatants were reduced to dryness in vacuo using a concentrator 271 
plus (Eppendorf, Hamburg, Germany) and resuspended in 150 µL of distilled water containing 272 
1% formic acid and 50 µL of methanol, which was then centrifuged at 16,100 g for 10 min and 273 
10 μL aliquots of the supernatant analysed by UHPLC-HRMS. The recoveries values of the 274 
internal standard were of 79 ± 16% (n=78). 275 
 276 
Non-targeted analysis of urine and plasma by UHPLC-HR-MS.  277 
Aliquots of selected plasma and urine samples were analysed using a Dionex Ultimate 3000 278 
RS UHPLC system comprising of a UHPLC pump, a PDA detector scanning from 200 to 600 279 
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nm, and an autosampler operating at 4 °C (Thermo Scientific). The HPLC conditions were 280 
previously described by Corona et al., (20) with some modifications. Briefly, reverse phase 281 
separations were carried out using a 100 x 2.1 mm i.d. 1.8 µm Zorbax SB C18 (Agilent) 282 
maintained at 25 °C and eluted at a flow rate of 0.2 mL/min with a 50 min gradient of 3-70% 283 
of 0.1% acidic methanol in 0.1% aqueous formic acid. After passing through the flow cell of 284 
the PDA detector the column eluate was directed to an ExactiveTM Orbitrap mass spectrometer 285 
fitted with a heated electrospray ionization probe (Thermo Scientific) operating in negative 286 
ionization mode. Analyses were based on scanning from 100 to 1000 m/z, with in-source 287 
collision-induced dissociation at 25.0 eV. The capillary temperature was 350 °C, the heater 288 
temperature was 150 °C, the sheath gas and the auxillary gas flow rate were both 25 and 5 289 
units, respectively, and the sweep gas was 4 and the spray voltage was 3.00 kv. Data acquisition 290 
and processing were carried out using Xcalibur 3.0 software. 291 
Untargeted analysis of the selected urine and plasma samples was performed using mass 292 
spectral data from the orbitrap analysis applied to the Compound Discoverer software (version 293 
2, Thermo Fisher Scientific Inc.). The Compound Discover application processes the raw data 294 
in called processing workflows that can be defined on the basis of the nature of the experimental 295 
setup. In our case, the workflow selected was 'untargeted metabolomics workflow' that includes 296 
retention time alignment, component detection, grouping, elemental composition prediction, 297 
gap filling, hide chemical background (using blanks), ID using mzCloud and ChemSpider and 298 
differential analysis. The parameters were adjusted to our experimental conditions. Samples 299 
were grouped and labelled according to our experimental design, either before or after 300 
supplementation of seaweed capsule, 4 The output, as peak areas for the detected peaks was 301 
used to develop a multivariate data analysis by Orthogonal Partial Least Square Discriminant 302 
Analysis (OPLS-DA). Analysis of seaweed phenolics in blood and urine was also undertaken 303 
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by HPLC-DAD analysis (reported in Supplemental Tables 4 & 5) in a manner consistent with 304 
previous studies (15,20). 305 
 306 
Power calculations and statistical analyses 307 
Power calculations were performed for the primary endpoint of the change in DNA damage 308 
in peripheral blood mononuclear cells. Based on data from a previous study (24), 72.6 309 
participants were needed to detect a 25% change in DNA damage in lymphocytes (α 0.05).   310 
All values are expressed as mean ± SD, unless otherwise specified. The mean values are 311 
reported for all participants (n=78) during both treatment phases (SPE, Maltodextrin). 312 
Significant associations (P>0.05) between outcome variables including DNA damage  and 313 
possible cofounders (age, gender, BMI) were identified at baseline using bivariate correlations 314 
or independent t-tests, where appropriate.  Therefore, data was also analysed by stratification 315 
of increasing risk, including overweight participants (n=42) and obese participants (n=36). All 316 
biochemical analysis was conducted in duplicates, unless otherwise stated, and the mean values 317 
taken as the final result. For all markers, the results are presented as treatment effects. This was 318 
undertaken by calculating individual differences between pre- and post- values for both control 319 
and treatment phases for each subject. Paired T-tests were then carried out on the difference 320 
scores (post-treatment value minus pre-treatment values) for both treatment phases (SPE and 321 
Maltodextrin). Significance level was set at P<0.05. All statistical analyses were performed 322 
using the Statistical Package for the Social Sciences (SPSS) for Windows version 22.0 (SPSS 323 
Inc., Chicago, IL, USA). 324 
 325 
Multivariate Data Analysis 326 
Data were obtained as peak areas from the Compound Discover automatic integration software 327 
and consisted of 2194 and 3289 potential metabolites (or features) in urine and plasma samples, 328 
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respectively. Relative peak areas of the metabolites (normalized by the total urine excretion of 329 
each subject) obtained by UPLC-HRMS were imported into MATLAB R2015b (Mathworks, 330 
USA). PLS toolbox v.8.5 (Eigenvector, USA) and homemade scripts were used. Principal 331 
component analysis (PCA) and hierarchical cluster analysis (HCA) are the most widely used 332 
tools to explore similarities and patterns among samples where data grouping are unclear. 333 
Moreover, the orthogonal partial least squares discriminate analysis (OPLS-DA) method was 334 
performed as a typical supervised multivariate methodology used in metabolomics studies 335 
(30,31). Several data pre-processing transformations were performed and evaluated, such as 336 
Probabilistic Quote Normalization (PQN), Log transformation, mean centering, pareto scaling 337 
and auto-scaling. In our case, PQN and autoscaling were selected as pre-processing techniques 338 
to reach the lowest root mean square error (RMSE) in an iterative process. A re-sampling 339 
method, cross-validation k-fold cross validation (k=5) was also used to evaluate the number of 340 
latent variables (according to the lowest RMSE) and the prediction ability of our models. To 341 
reduce the impact of the random split of CV-participants, the mean values of the estimated 342 
results were obtained after 20 random 5-fold CV. Urine models provided successful 343 
classification results at the cross validation step and achieved good prediction parameters that 344 
can be explained by the area under the curve values (1.00 and 0.895). Based on the plasma data 345 
set and classes selected a discriminant model could not be developed. Moreover, the Variable 346 
Importance in Projection (VIP) is the widely known metric that is used to identify potential 347 
markers in metabolomics studies (32). VIP is a weighted sum of squares of the PLS weight 348 
which indicates the importance of the variable to the whole model. The cut off VIP value 349 
selected in our study was 2. The potential markers were extracted from the two models to 350 
compare the results obtained.  351 
 352 
RESULTS 353 
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Baseline characteristics 354 
Eighty participants (males n=39, females n=41) were enrolled on this 24-week randomised, 355 
double-blind, placebo-controlled crossover trial. The intervention was conducted as per the 356 
protocol and there were no adverse events associated with the intervention. The study 357 
population had a mean group age of 42.7±7.1 years and a mean BMI of 30.2±3.9 kg/m2. The 358 
study had an overall compliance of 97% with 78 participants completing the 24-week study; 359 
two participants withdrew from the study at the midpoint for personal reasons and compliance 360 
was not significantly different by treatment group or time period (P>0.05) (Figure 1). There 361 
were no significant differences between the participants in age and physical characteristics at 362 
the beginning of either treatment phase (Table 2). 363 
 364 
Habitual dietary intake  365 
Dietary analysis of habitual intake (midpoint) during both treatment phases (SPE, 366 
Maltodextrin) of the crossover trial is described in Table 3. There were no significant 367 
differences between treatment phases for any of the macronutrients or micronutrients analysed 368 
indicating that the seaweed phenolic extract did not affect the habitual food consumption 369 
patterns in the study population. 370 
 371 
Effects of seaweed (poly)phenol  extract on DNA damage  372 
The basal levels of DNA damage observed in the study were consistent with previous studies 373 
with a mean group average of 6.72 ± 2.48% tail DNA (data not shown). In response to an 374 
oxidative challenge with 150 µM H2O2, DNA damage was increased to an average of 375 
approximately 34 ± 7% tail DNA in both the placebo and SPE phase in all participants as 376 
reported in Table 4. The 8-week intervention with a seaweed phenolic extract resulted in a 377 
significant reduction in basal DNA damage, as measured by the Comet assay, in obese 378 
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participants only (BMI >30 kg/m2), with a significant reduction (P=0.044) in basal DNA 379 
damage observed (Table 4). A significant reduction was not observed in the total population 380 
(n=78) nor in the overweight participants (n=42), either in terms of a challenge response or in 381 
basal levels.  Additionally,  consumption of seaweed phenolic extract also significantly reduced 382 
(P=0.009) basal DNA in males only with a mean group change value of  -0.8 ± 2.5 % tail DNA 383 
(SPE) compared to 0.9 ±2.8% tail DNA in the control. No significant effects where observed 384 
for females.  385 
 386 
Total oxidative capacity of seaweed phenolics 387 
Figure 2 shows the total oxidative capacity (peroxide levels) in plasma samples from all 388 
participants (n=78), in overweight participants (n=42) and in obese participants (n=36) 389 
measured after the placebo and seaweed capsule intervention. There were no significant 390 
changes from baseline after either treatment phase (SPE, Maltodextrin) in all participants 391 
(n=78) nor in overweight (n=42) or obese (n=36) sub groups. However the consumption of 392 
seaweed phenolic extract also significantly reduced (P=0.018) TOC in females only with a 393 
mean group change value of  -7.44 ± 29.37  (SPE) compared to 4.33 ± 22.36 in the control. No 394 
significant effects where observed for males. 395 
Effects of seaweed (poly)phenol  extract on blood lipids and CRP 396 
Table 4 shows the pre- and post- values, as well as the percentage change, for both the 397 
placebo phase and the SPE phase for each blood lipid biomarker and CRP.  An 8-week 398 
supplementation with seaweed (poly)phenol extract did not significantly affect any 399 
cardiovascular risk marker. 400 
Effects of seaweed (poly)phenol  extract on inflammatory markers 401 
F2α-isoprostane levels at baseline were 392 ± 219 pg/ml (data not shown). A high degree of 402 
inter-individual variation was observed, and the 8-week SPE intervention did not exhibit a 403 
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significant effect on this marker of oxidative stress (Table 4). There were no significant 404 
differences for any of the inflammatory cytokines measured in either treatment phase (SPE, 405 
Maltodextrin) for all of the participants (n=78), in the overweight participants (n=42) or in the 406 
obese participants (n=36) (Figure 4). Nor where significant effects observed in the cytokine 407 
profiles when examined by ratio of TNF-α to IL-10, IL-1β to IL-10, IL-6 to IL-10 and CRP to 408 
IL-10, according to Laird et al. (29) 409 
Bioavailability of seaweed phenolics, untargeted Analysis 410 
Initially an unsupervised PCA model was carried out (Figure 4A) on the urine data from all 411 
78 participants. The first component of the PC1 vs PC2 scores plot obtained from the data set 412 
explained 23.14% of the total variance showing a clear trend among some of the participants 413 
compared to the rest. Moreover, a hierarchical cluster analysis was performed to verify this 414 
natural aggrupation pattern among the 78 participants suggesting, two clusters among all the 415 
participants (Figure 4B) which share, accounting for the inter-individual differences associated 416 
with differences in the urinary metabolite profiles. For instance, recent studies suggest that 417 
individuals can be clustered into distinct groups based on their gut microbiome composition, 418 
functional metabolism (33) or individual responses to obtain markers of a specific treatment, 419 
minimizing the inter-individual data that are not the target of the study. In order to elucidate 420 
the observed variability between these two groups, two supervised models were performed, 421 
one with the urinary profiles from all the participants before the seaweed consumption and 422 
another one with the urinary profiles from all the participants after seaweed consumption. Both 423 
supervised models verified differences between the two groups of individuals (Group 1 and 424 
Group 2) and provided successful classification results at the cross validation step and achieved 425 
in the pre-treatment and post-treatment samples 95% and 98% sensitivity (participants of the 426 
class of interest correctly assigned to their class) and 100% and 100% specificity (participants 427 
not belonging to the class of interest were correctly not assigned to that class), respectively 428 
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(Supplemental Figure 1). It is noteworthy that even stratifying for BMI category, the 429 
multivariate analysis of the urine profiles did not show clear differentiation of the metabolome 430 
between obese or overweight individuals. 431 
By using the preliminary information provided by PCA and HCA related to the stratification 432 
of the individuals into groups which share a common excretion profile before and after 433 
supplementation with seaweed capsules, two data sets were analysed. The individuals were 434 
stratified into two groups; Group 1 including 70 participants; and Group 2 including 8 435 
participants (S58, S60, S61, S71, S76, S78, S79, S83, all being overweight individuals). Two 436 
supervised OPLS-DA models were built to discriminate according to the seaweed treatment in 437 
both models (Figure 5). In our study we used two latent variables (LV) and the sensitivity and 438 
specificity values were set to 100% at the calibration step recognition ability of the two models. 439 
These analyses showed that the human urine metabolome in both groups of participants was 440 
modified after the 8-week supplementation with seaweed (poly)phenol extract compared to 441 
baseline urine metabolic profiles. Using the loadings plot and the variable importance in 442 
projection values (VIP) we ascertained important contributors between the modelled classes 443 
and therefore identified the compounds responsible for the difference in the urine metabolic 444 
profile before and after 8-weeks seaweed (poly)phenol  extract consumption in both groups. 445 
VIP is the widely known metric that is used to identify potential markers (metabolites) in 446 
metabolomics studies. Further, the urine scores plot allowed the identification of those 447 
metabolites which appeared after the seaweed (poly)phenol  extract intake (Figure 5) in both 448 
groups of participants.  449 
 450 
The main contributors to metabolome differentiation in the urine before and after seaweed 451 
consumption in both groups of participants are described in Supplemental Table 1 and Table 2 452 
(Supplemental Material). Positive loading values (x axis) and higher VIP values (VIP>2.0) 453 
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were detected  in urine after seaweed consumption and were the responsible of the observed 454 
differences between the participants classes (post ingestion vs non ingestion of seaweed 455 
(poly)phenol  extract). Urine metabolites tentatively identified as pyrogallol/phloroglucinol 456 
sulfate, hydroxytrifurahol A-sulfate and dioxinodehydroeckol glucuronide are considered clear 457 
biomarkers of seaweed consumption in Group 1 while C-O-C dimer of phloroglucinol-sulfate, 458 
C-O-C-dimer of phloroglucinol, fucophloroethol-glucuronide, diphlorethol sulfates and 459 
dioxinodehydroeckol glucuronide are those biomarkers of seaweed consumption in Group 2. 460 
All of them have shown high values in the variable importance in the projection (values > 2) 461 
(Table 5). 462 
Based upon the identified seaweed (poly)phenol metabolites, the total amount of seaweed 463 
metabolites excreted in urine varied noticeably between participant ranging from 0.001  to 464 
4.140 mmoles, with a group average of 1.29 +/- 0.88 mmoles.  25% of the population (19/78) 465 
appeared to be low excretors with urinary seaweed metabolites excretion less than 0.5 mmoles, 466 
55% of the population (43/78) were medium excretors with an urinary seaweed excretion 467 
between 0.5 and 2 mmoles, while 20% of the population (16/78) where high excretors with 468 
total seaweed metabolites concentrations  >2 mmoles (see Supplemental Table 6 ).  469 
The plasma metabolome demonstrated no clear differentiation for participants in either 470 
treatment phase (data not shown), nor with exploration of the data by PCA or HCA. 471 
Consequently no exposure biomarkers could be defined for plasma samples taking into account 472 
all the participants (n=78).  473 
 474 
DISCUSSION 475 
The association of seaweed consumption with reduced risk factors for CVD has been tested 476 
largely within in vitro or animal models, and only limited human data exists to substantiate the 477 
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proposed beneficial properties of seaweeds (12,13,34). To the best of our knowledge this trial 478 
is the first comprehensive study to investigate the in vivo bioactivity and bioavailability of 479 
seaweed (poly)phenolics on biomarkers of inflammation and oxidative stress in overweight 480 
and obese individuals. Participant retention rates were high (98%) and self-reported SPE 481 
capsule intake (97%) indicated that the intervention was implemented successfully in this 482 
group of participants. There was, however, no significant difference between the intervention 483 
(SPE capsule) and control (placebo capsule) phases for markers of oxidative stress, antioxidant 484 
status or inflammation in the population as a whole (n=78). Subset analysis, stratifying for BMI 485 
category, showed a significant albeit modest difference in DNA damage in the obese 486 
population (n=36). This is consistent with Park et al. (35) who tested astaxanthin, a natural 487 
carotenoid in the form of microalgae Haematococcus pluvialis in 14 healthy females (2 mg/d 488 
extract for 8 weeks) demonstrating a significant reduction in the oxidative damage marker 489 
plasma 8-hydroxy-2’-deoxyguanosine. Obese individuals are associated with increased DNA 490 
damage, higher oxidant status and increased oxidative damage to macromolecules a group and 491 
are at higher risk of chronic disease (36-39). In our study, an overweight/obese population (age 492 
30-65 years and a BMI >25 kg/m2) was shown to have significantly reduced basal levels of 493 
lymphocyte DNA damage (by 23%) but only in the obese population subset (n=36) following 494 
supplementation. Both seaweed-based intervention studies support data from in vitro studies 495 
indicating anti-genotoxic activity for seaweed extracts on a range of cell lines (40,41) including 496 
the SPE extract used in the study (15). Although a mechanism was not determined for the 497 
observed reduction in DNA damage in the obese group activate Nrf2-mediated cytoprotection 498 
may be involved, as seaweed (poly)phenols such as eckol are anti-genotoxic (42) and can 499 
activate Nrf2-mediated HO-1 induction (43,44) consistent with effects observed for 500 
(poly)phenols from terrestrial sources (45,46). Park et al. (35) also observed a significant 501 
reduction in plasma CRP levels, an acute marker of inflammation. Although in our study we 502 
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observed a 28% decrease in CRP levels in response to seaweed extract consumption, this 503 
change was not significant. However, a similar study investigating the effect of consuming 504 
Palmaria palmata (5 g/day) incorporated into bread found that it significantly increased CRP 505 
by 16%, suggesting that P. palmata stimulates inflammation rather than reducing it (47). Park 506 
et al. (35) reported that there was no difference in TNF and IL-2 concentrations, but plasma 507 
IFN-and IL-6 increased on week 8 in participants given 8mg astaxanthin. Within this study, 508 
we similarly observed no significant changes in IL-2 or TNF, nor did we see an alteration in 509 
IFN-or IL-6. The seaweed extract tested did not affect immune function (cell mediated and 510 
humoral immune responses as tested by the cytokine markers) following supplementation.  511 
 512 
In order to evaluate the seaweed molecules responsible for its modest beneficial effects in vivo 513 
and the potential biological markers linked to seaweed consumption, an untargeted approach 514 
comparing the metabolic profiles between urine and plasma samples of 78 individuals who 515 
consume seaweed capsules have been carried out. As a first step, we have determined 516 
differences in the urine metabolic profiles between participants being able to stratify the 517 
individuals into groups which share common excretion metabolite profile before and after 518 
seaweed capsule supplementation. Urinary profiles of these two groups were statistically 519 
different between each other and the metabolites responsible for this discrimination have been 520 
selected as potential biomarkers of seaweed consumption (Table 5). Subsequently, the 521 
quantification of these potential biomarkers within all participants revealed substantial inter-522 
individual variation in the concentration of seaweed metabolites excreted in urine by the 523 
participants ranging from 0.001 to 4.140 mmoles. Besides, the outcomes of the comprehensive 524 
multivariate analysis of the metabolite profiles shows, as expected, person-to-person variation 525 
in the 0-24h urinary excretion of seaweed (poly)phenols, probably due to differences in gut 526 
microbiota and no strict living conditions of the participants. As a consequence of these inter 527 
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individual differences, the 78 participants involved in this study can be grouped by their 528 
dissimilarity to metabolize seaweed (poly)phenols in two well established groups. For instance, 529 
group 1 of individuals is characterized by greater excretion of seaweed derived metabolites 530 
such as pyrogallol/phloroglucinol sulfate, hydroxytrifurahol A-sulfate and 531 
dioxinodehydroeckol; while participants belonging to group 2 C-O-C dimer of phloroglucinol-532 
sulfate, C-O-C dimer of phloroglucinol, fucophloroethol-glucuronide, diphlorethol sulfates and 533 
dioxinodehydroeckol glucuronide in low concentrations. This inter-individual variation in the 534 
absorption of seaweed polyphenols has been observed in the bioavailability of dietary 535 
(poly)phenols such as orange juice, cranberry and pomegranate (48-50). 536 
The results from the non-targeted approach confirmed the presence of seaweed phenolic 537 
metabolites, and can be divided into a) phase II sulphated and glucuronidated metabolites 538 
related to the targeted components described earlier by Corona et al. (20) (supplemental Tables 539 
4,5); arguably formed in the liver; b) an extended list of unknown compounds which may be 540 
potential breakdown products or metabolites of the original seaweed (poly)phenols catabolised 541 
by the colonic bacteria but further studies would be required to confirm the identity of these 542 
unknown compounds.  Poor absorption of the high molecular weight phlorotannins in the upper 543 
gastrointestinal tract following acute consumption of our seaweed (poly)phenolic extract as 544 
reported (20) likely results in them reaching the colon and becoming subject to microbial 545 
fermentation to lower molecular weight derivatives; recently confirmed by in vitro  gut 546 
modelling of SPE by colonic microbiota (15). The urinary metabolite profiles of seaweed 547 
phenolics from the low and high excretors clearly indicated a high inter-individual variation in 548 
metabolism similar to that observed in terrestrial plant phenolics, and no single common 549 
metabolite or pattern could be detected following seaweed consumption. It is possible that 550 
inter-individual variation in gut microbiota underlie these metabolic changes and were 551 
responsible for the observed differences. That said, the study of bioavailability of seaweed 552 
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polyphenolics remains challenging due to the high range of molecular weight compounds 553 
present, and their characterisation is complicated further by the lack of commercially available 554 
standards. Other limitations of the present study include a relatively short-term intervention, 555 
results cannot therefore be extrapolated to long-term chronic consumption. Participants in this 556 
study may not be representative of the general overweight population of Northern Ireland as 557 
they were mostly recruited from the University of Ulster staff and local residents. While 558 
lymphocyte DNA damage (spontaneous DNA SBs) is considered appropriate for the 559 
substantiation of EFSA health claims in the context of protection against generic DNA damage, 560 
a lesion specific enzyme such as (ENDO III) would have been required for a claim related to 561 
oxidative DNA damage (51). Finally, the study population number may have been too small to 562 
yield significant results in intercellular cytokines. These factors should be considered for the 563 
design of future studies in this area. 564 
To conclude, to the best of our knowledge, this work represents the first comprehensive 565 
study represents the first comprehensive study involving 78 human participants investigating 566 
the bioavailability of seaweed (poly)phenolics. Consumption of SPE, decreased DNA damage 567 
albeit to a modest extent in obese individuals only; with no clear effects on clinical markers of 568 
inflammation. While untargeted analysis identified novel urinary biomarkers of seaweed 569 
consumption and highlighted a high degree of inter-person variation in the metabolism of 570 
seaweed phenolics. Future studies that address the ingestion of seaweed phenolics will need to 571 
consider and adjust for these parameters, including the importance of establishing an 572 
individual’s capacity for metabolising (poly)phenol (52-54). 573 
 574 
 575 
 576 
 577 
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Table 1. Key components of phlorotannin rich basic seaweed extract, High Molecular Weight 
(HMW) seaweed extract fraction, and blend used for intervention capsules (SPE). 
Extract component 
Basic seaweed 
extract 
HMW seaweed 
extract fraction 
Blend  
(SPE capsule) 
mg/175mg of extract mg/50mg of extract mg/400mg capsule 
Phlorotannin 61.25 46.05 107.3 
Iodine  0.48 0.02 0.5 
Maltodextrin1 0 0 175 
Minerals 39.38 13 52.38 
Fucoxanthin 0 36.5 36.5 
Laminarin as glucose  10.68 1.75 12.43 
Fucoidan as fucose 0 <0.001 <0.001 
Mannitol  29.23 5.9 35.13 
Inorganic arsenic  <0.001 <0.001 <0.001 
Cadmium (LD 0.15mg/kg) <LD  <LD  <LD  
Mercury (LD 0.016mg/kg) <LD  <LD  <LD  
Lead (LD 1.1mg/kg) <LD  <LD  <0.001 
Tin (LD 1.7mg/kg) <LD  <LD  <LD  
1maltodextrin was added to the capsule formulation as an excipient. 
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Table 2. Baseline characteristics of the study population (n=80). 
 
 
 
 
 
 
 
 
 
     
No significant differences P>0.05, Paired T Test. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Placebo 
treatment phase 
(n=80) 
SPE        
treatment phase 
(n=80) 
Age (y) 42.8 ± 7.2 42.9 ± 7.1 
Gender (M/W) 20/20 19/21 
Height (m) 1.71 ± 0.08 1.72 ± 0.10 
Weight (kg) 88.9 ± 14.1 89.1 ± 17.3 
BMI (kg/m2) 30.3 ± 3.5 30.0 ± 4.4 
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Table 3. Habitual nutrient intake of subjects during intervention study 
Variable intake 
Placebo 
treatment 
phase 
(n=77)1 
SPE  
treatment 
phase 
(n=77) 
% 
Change2 
P 
value3 
Energy (kcal/d) 1949 ± 5904 2057 ± 684 5 0.110 
Protein (g/d) 79.4 ± 28.6 79.9 ± 25.3 0.5 0.782 
Carbohydrate (g/d) 220.6 ± 72.1 231.3 ± 84.2 5 0.278 
Total fat (g/d) 78.6 ± 26.5 85.2 ± 34.8 8 0.058 
Saturated fat (g/d) 29.0 ± 10.2 30.7 ± 15.3 6 0.417 
Monounsaturated fat (g/d) 24.4 ± 9.3 26.8 ± 12.4 9 0.112 
Polyunsaturated fat (g/d) 12.1 ± 5.4 13.5 ± 6.4 10 0.059 
Fibre (g/d)5 12.9 ± 6.2 13.3 ± 4.8 3 0.259 
Vitamin C (mg/d) 71.8 ± 50.5 69.4 ± 47.1 -3 0.909 
Vitamin E (mg/d) 7.17 ± 3.7 7.67 ± 4.0 7 0.279 
Folate (µg/d) 223.9 ± 98.3 228.2 ± 85.5 2 0.370 
Carotene (µg/d) 2821 ± 1900 2553 ± 1706 -11 0.185 
1S66 did not complete a food diary in either phase. 2 Calculated from SPE phase – Placebo 
phase. 3 Mean treatment group values were not significantly different between phases, P>0.05 
(Wilcoxin signed rank test). 4 Mean ± SD. 5Calculated using the Englyst method. 
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Table 4. Effects of seaweed polyphenol extract on lymphocyte DNA damage, CRP, blood lipids and F2 isoprostanes  
Data is presented as treatment affects, calculated based on individual differences between pre- and post- values for both control and treatment 
phases for each subject. Paired T-tests were then carried out on the difference scores (post-treatment value minus pre-treatment values) between 
treatment (Seaweed phenolic extract capsule) and placebo control phase (maltodextrin). Significance level was set at P<0.05 (one-tailed T test). 
       
   Total 
(n=78)  
    
Overweight 
 (n=42) 
  
   
 
Obese 
 (n=36) 
    
Blood marker 
Average 
baseline 
value 
Placebo 
treatment 
effect 
SPE treatment 
effect 
P 
value 
Average 
baseline 
value 
Placebo 
treatment 
effect 
SPE 
treatment 
effect 
P value 
Average 
baseline 
value 
Placebo 
treatment 
effect 
SPE 
treatment 
effect 
P value 
                
DNA damage – 
basal   (% Tail) 
6.72 ± 2.48 0.74 ± 2.86 -0.41 ±  3.13 0.350 6.59 ± 2.80 0.32 ± 2.14 0.57 ± 3.24 0.129 6.91 ± 2.00 1.81 ± 4.50 0.15 ± 2.93 0.044 
DNA damage - 
H2O2 (%Tail) 
34.2 ± 7.00 -1.56 ± 6.60 -2.03 ± 6.40 0.390 35.2 ± 7.11 0.13 ± 2.19 0.76 ± 1.66 0.062 32.8 ± 6.69 1.26 ± 2.09 0.54 ± 1.54 0.111 
CRP (mg/ml) 2.67 ± 3.9 0.01 ± 3.3 -0.83 ± 4.9 0.429 2.59 ± 4.69 0.00 ± 3.40 -1.32 ± 6.22 0.348 2.80 ± 2.56 -1.81 ± 11.82 0.72 ± 5.15 0.258 
Cholesterol 
(mmol/l) 
5.20 ± 0.77 -0.06 ± 0.57 -0.10 ± 0.57 0.256 5.18 ± 0.82 0.01 ± 0.55 -0.53 ± 0.54 0.201 5.24 ± 0.73 -0.13 ± 0.58 -0.15 ± 0.60 0.419 
Triglycerides 
(mmol/l) 
1.51 ± 0.94 0.01 ± 0.82 0.04 ± 0.96 0.385 1.34 ± 0.72 0.07 ± 0.79 -0.04 ± 0.48 0.278 1.75 ± 1.15 -0.06 ± 0.85 -0.02 ± 1.34 0.497 
HDL (mmol/l) 1.37 ± 0.32 -0.01 ± 0.15 0.03 ± 0.15 0.187 1.46 ± 0.31 0.01 ± 0.16 -0.03 ± 0.15 0.150 1.25 ± 0.32 -0.04 ± 0.11 -0.04 ± 0.14 0.446 
LDL (mmol/l) 3.16 ± 0.1 -0.08 ± 0.5 -0.06 ± 0.50 0.478 3.13 ± 0.69 -0.07 ± 0.57 0.01 ± 0.45 0.383 3.20 ± 0.67 -0.09 ± 0.56 -0.13 ± 0.56 0.412 
F2Isoprostanes 
(pg/ml) 
393 ± 220 -10 ± 182 -6 ± 138 0.374 342 ± 128 28 ± 152 -29 ± 108 0.130 439 ± 272 -44 ± 204 14 ± 158 0.283 
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Table 5. Phlorotannins metabolites tentatively identified in human urine samples from Group 1 (70 subjects) and Group 2 (8 subjects) after 
seaweed capsule consumption. 
ID VIP value Rt (min) Experimental Molecular Weight Predicted Formula Metabolite putative identification Ratio1  
Group 1 (72 subjects) 
652 2.06 25.6 205.9881 C6H6O6S Pyrogallol/phloroglucinol sulfate 1.5  
800 2.28 25.8 205.9881 C6H6O6S Pyrogallol/phloroglucinol sulfate 1.2  
1472 3.86 24.9 205.9881 C6H6O6S Pyrogallol/phloroglucinol sulfate 1.1  
1352 4.26 25.6 486.1727 C26H30O7S Hydroxytrifuhaol A-glucuronide 2.0  
1453 3.83 25.4 486.1727 C26H30O7S Hydroxytrifuhaol A-glucuronide 1.9  
1458 4.23 25.3 486.1727 C26H30O7S Hydroxytrifuhaol A-glucuronide 2.2  
1483 4.39 25.3 486.1727 C22H30O12 Hydroxytrifuhaol A-glucuronide 2.2  
1917 2.11 31.4 544.2881 C27H44O11 Dioxinodehydroeckol glucuronide 1.1  
 
Group 2 (8 subjects) 
293 2.08 9.5 327.0951 C12H8O9S C-O-C dimer of phloroglucinol-sulfate 1.2  
702 2.20 24.1 248.0315 C12H8O6 C-O-C dimer of phloroglucinol 1.2  
853 2.08 27.8 797.3186 C45H49O13 Fucophloroethol glucuronide 1.1  
1293 2.28 34.2 330.1675 C12H10O9S Diphlorethol sulfate 1.9  
1356 2.31 34.1 330.1675 C12H10O9S Diphlorethol sulfate 1.7  
1633 2.07 35.1 544.2152 C27H44O11 Dioxinodehydroeckol glucuronide 1.2  
 
ID, identification number. VIP (variable influence in projection) is a variable that summarizes the importance of X variables to the OPLS-DA 
model. Variables with values > 2 were the most influential in the model.  All predicted formula derived with < 5 ppm mass accuracy data.  
1Ratio: seaweed capsule consumption/placebo consumption. 
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FIGURE 1. CONSORT DIAGRAM. Progress of participants through the intervention study. 
FIGURE 2. Comparison of the effects of SPE supplementation phase () with that of a placebo 
phase () on total oxidative capacity (TOC) in the total study population (n=78), in overweight 
(n=42), and in obese (n=36). All values were measured in duplicate expressed as mean ± SD. 
TOC is represented as the mean of the individual difference values (after – before 
supplementation) in the SPE and placebo treatment phases.  
FIGURE 3. Comparison of the effects of SPE supplementation phase () with that of a placebo 
phase () on cytokine levels in the total study population (n=78), in overweight (n=42), and 
in obese (n=36). All values were measured in duplicate expressed as mean ± SD. Cytokines 
were measured as the mean of the individual difference value (after – before supplementation) 
in the SPE and placebo treatment phases. Change in mean treatment group values were not 
significantly different between treatment phases, P>0.05 (Paired T Test; one-tailed test). 
M.F.I.; Mean Fluorescence Intensity. 
FIGURE 4. Principal Component Analysis (PCA) (A) and Hierachical Cluster Analysis 
Cluster (HCA) (B) of urinary profiles before (♦) and after (■) seaweed consumption by 80 
participants. The HCA was calculated based on Eucledian distances and the Ward hierachical 
agglomerative method. The PC explained 23.14% of the total variance (PC-1 14.8% and PC-2 
8.34%). 
FIGURE 5 A) OPLS-DA scores and B) loadings of the urine samples belong to group of 
participants 1 (70 participants). C) OPLS-DA scores and D) loading of urine samples belong 
to group of participants 2 (8 participants) before (♦) and after (■) seaweed ingestion. (Circles 
shown in the graph represent a confidence of 95%). LV1: latent variable 1; LV 2: latent variable 
2. The cut off VIP value selected to be 2. For VIP scores identification see Table 5 and 
Supplemental Table 1. 
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FIGURE 1  
Assessed for eligibility (n=244) 
Excluded (n=157) 
 BMI <25 kg/m2 (n=71)  
 Taking supplements (n=7) 
 Taking medication/diagnosed medical 
condition (n=53) 
 Age <30 years (n= 13) 
 Pregnant (n=4) 
 Opted out due to personal reasons (n=7) 
 Smoker (n=2) 
Suitable (n=87) 
Randomised (n=80) 
 
Intervention phase (n=40) 
Seaweed capsule 
1 x 400mg/day for 8 weeks 
 
Control phase (n=40) 
Placebo capsule 
1 x 400mg/day for 8 weeks 
 
8-week washout phase 
Discontinued intervention 
Due to personal reasons (n=1) 
 
8-week washout phase 
Discontinued intervention 
Due to personal reasons (n=1) 
 
Control phase (n=39) 
Placebo capsule 
1 x 400mg/day for 8 weeks 
 
Intervention phase (n=39) 
Seaweed capsule 
1 x 400mg/day for 8 weeks 
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